These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials. Richardus JH, Withington SG, Anderson AM, Croft RP, Nicholls PG, Van Brakel WH, Smith WC. Lepr Rev; 2003 Dec; 74(4):319-27. PubMed ID: 14750577 [Abstract] [Full Text] [Related]
11. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). Smith WC, Anderson AM, Withington SG, van Brakel WH, Croft RP, Nicholls PG, Richardus JH. BMJ; 2004 Jun 19; 328(7454):1459. PubMed ID: 15159285 [Abstract] [Full Text] [Related]
12. Impairments and Hansen's disease control in Rondônia state, Amazon region of Brazil. De Oliveira CR, De Alencar Mde J, De Sena Neto SA, Lehman LF, Schreuder PA. Lepr Rev; 2003 Dec 19; 74(4):337-48. PubMed ID: 14750579 [Abstract] [Full Text] [Related]
13. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R, Schreiber C. Headache; 2008 Jun 19; 48(6):900-13. PubMed ID: 18047501 [Abstract] [Full Text] [Related]
14. Leprosy type 1 (reversal) reactions and their management. Walker SL, Lockwood DN. Lepr Rev; 2008 Dec 19; 79(4):372-86. PubMed ID: 19274984 [Abstract] [Full Text] [Related]
15. Effect of corticosteroid usage combined with multidrug therapy on nerve damage assessed using nerve conduction studies: a prospective cohort study of 365 untreated multibacillary leprosy patients. Capadia GD, Shetty VP, Khambati FA, Ghate SD. J Clin Neurophysiol; 2010 Feb 19; 27(1):38-47. PubMed ID: 20087206 [Abstract] [Full Text] [Related]
17. Sensitivity and specificity of nerve palpation, monofilament testing and voluntary muscle testing in detecting peripheral nerve abnormality, using nerve conduction studies as gold standard; a study in 357 patients. Khambati FA, Shetty VP, Ghate SD, Capadia GD. Lepr Rev; 2009 Mar 19; 80(1):34-50. PubMed ID: 19472851 [Abstract] [Full Text] [Related]
18. A field trial of detection and treatment of nerve function impairment in leprosy--report from national POD pilot project. Jiang J, Watson JM, Zhang GC, Wei XY. Lepr Rev; 1998 Dec 19; 69(4):367-75. PubMed ID: 9927809 [Abstract] [Full Text] [Related]
19. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Vinik AI, Bril V, Kempler P, Litchy WJ, Tesfaye S, Price KL, Bastyr EJ, MBBQ Study Group. Clin Ther; 2005 Aug 19; 27(8):1164-80. PubMed ID: 16199243 [Abstract] [Full Text] [Related]
20. Effect of drug treatment on electroneurological measures of peripheral nerve function in leprosy patients. Mendis S, Somasiri KG, Chularatna W. Ceylon Med J; 1993 Dec 19; 38(4):174-7. PubMed ID: 8143332 [Abstract] [Full Text] [Related] Page: [Next] [New Search]